Scholarlink

Background <p>Gastric cancer (GC) progression involves changes in immune responses, inflammation, and coagulation. The prognostic value of related biomarkers remains unclear. This study aimed to develop a novel immune-inflammation-fibrinogen score (FSL score) to predict outcomes in GC patients after radical gastrectomy.</p> Methods <p>Clinicopathological data from 401 GC patients enrolled in a randomized controlled trial (2015–2016; ClinicalTrials.gov: NCT02327481) were retrospectively analyzed as the training cohort, with 173 patients included for external validation. Cox regression was used to construct the FSL score based on preoperative hematological markers and to evaluate its association with overall survival (OS) and recurrence-free survival (RFS). A nomogram incorporating the FSL score and clinicopathological factors was developed and evaluated using the C-index, time-dependent AUC, calibration curves, AIC, BIC, and decision curve analysis (DCA), and compared with the AJCC 8th TNM staging system.</p> Results <p>Patients with high FSL scores had significantly better 3-year OS (training cohort: 87.4% vs. 71.3%, <i>p</i> = 0.001; validation cohort: 68.4% vs. 42.6%, <i>p</i> = 0.009) and RFS (training cohort: 81.0% vs. 67.6%, <i>p</i> = 0.001; validation cohort: 72.4% vs. 54.9%, <i>p</i> = 0.025). The FSL score independently predicted OS and RFS (all <i>p</i> &lt; 0.05). A nomogram integrating the FSL score, preoperative CEA level, pT stage, pN stage, and postoperative chemotherapy outperformed the TNM system for OS (C-index: 0.806 vs. 0.757; AIC: 1378.25 vs. 1395.73; BIC: 1390.49 vs. 1394.10) and RFS (C-index: 0.803 vs. 0.763; AIC: 1310.10 vs. 1319.08; BIC: 1320.11 vs. 1322.26), with good discrimination, calibration, and clinical utility confirmed by DCA and external validation.</p> Conclusions <p>The FSL score is a promising prognostic biomarker for GC patients undergoing radical gastrectomy. The proposed nomogram enables accurate and individualized survival prediction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Wei Zhao,
  • Qing Zhong,
  • Bao-Long Li,
  • Cai-Ming Weng,
  • Hao-Xiang Zhang,
  • Gang Wang,
  • Zhi-Quan Zhang,
  • Ying-Xin Wu,
  • Dong Wu,
  • Jun-Yu Chen,
  • Qi-Yue Chen,
  • Chao-Hui Zheng,
  • Chang-Ming Huang,
  • Jian-Wei Xie

摘要

Background

Gastric cancer (GC) progression involves changes in immune responses, inflammation, and coagulation. The prognostic value of related biomarkers remains unclear. This study aimed to develop a novel immune-inflammation-fibrinogen score (FSL score) to predict outcomes in GC patients after radical gastrectomy.

Methods

Clinicopathological data from 401 GC patients enrolled in a randomized controlled trial (2015–2016; ClinicalTrials.gov: NCT02327481) were retrospectively analyzed as the training cohort, with 173 patients included for external validation. Cox regression was used to construct the FSL score based on preoperative hematological markers and to evaluate its association with overall survival (OS) and recurrence-free survival (RFS). A nomogram incorporating the FSL score and clinicopathological factors was developed and evaluated using the C-index, time-dependent AUC, calibration curves, AIC, BIC, and decision curve analysis (DCA), and compared with the AJCC 8th TNM staging system.

Results

Patients with high FSL scores had significantly better 3-year OS (training cohort: 87.4% vs. 71.3%, p = 0.001; validation cohort: 68.4% vs. 42.6%, p = 0.009) and RFS (training cohort: 81.0% vs. 67.6%, p = 0.001; validation cohort: 72.4% vs. 54.9%, p = 0.025). The FSL score independently predicted OS and RFS (all p < 0.05). A nomogram integrating the FSL score, preoperative CEA level, pT stage, pN stage, and postoperative chemotherapy outperformed the TNM system for OS (C-index: 0.806 vs. 0.757; AIC: 1378.25 vs. 1395.73; BIC: 1390.49 vs. 1394.10) and RFS (C-index: 0.803 vs. 0.763; AIC: 1310.10 vs. 1319.08; BIC: 1320.11 vs. 1322.26), with good discrimination, calibration, and clinical utility confirmed by DCA and external validation.

Conclusions

The FSL score is a promising prognostic biomarker for GC patients undergoing radical gastrectomy. The proposed nomogram enables accurate and individualized survival prediction.